IntelGenx Corp. has completed an initial shipment of CBD Filmstrips in support of Heritage Cannabis Holdings Corp.’s Canadian market launch of its “CB4 Control” branded product. The CBD Filmstrips were produced at IntelGenx’s manufacturing facility under Canadian GPP conditions and registered as a product for sale with Health Canada as a cannabis product governed by the Cannabis Act.
Dr. Horst G. Zerbe, CEO of IntelGenx, commented, “Our partnership with Heritage Cannabis paved the way for our recent transition from a development-stage to a commercial-stage company. We are looking forward to continuing to work with Heritage Cannabis to make innovative and high-quality oral thin film products available to medical cannabis consumers.”
“We are proud that the CB4 Control filmstrips, based on IntelGenx’s Versafilm® platform, help comprise our new Opticann suite of branded products,” commented Umar Syed, President of the Medical Division at Heritage Cannabis. “We continue to believe the future of the oral cannabinoid market will be dominated by products based on innovative technologies such as VersaFilm® that are proven to deliver rapid and better absorption in a convenient dosage form.”
IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films. IntelGenx’s superior film technologies, including VersaFilm®, DisinteQ™, VetaFilm™ and transdermal VevaDerm™, allow for next generation pharmaceutical products that address unmet medical needs. IntelGenx’s innovative product pipeline offers significant benefits to patients and physicians for many therapeutic conditions. IntelGenx’s highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx’s state-of-the-art manufacturing facility offers full service by providing lab-scale to pilot- and commercial-scale production. For more information, visit www.intelgenx.com.